This site requires a more recent version of Adobe Flash Player to function properly.
Go here to get Flash.
Trefis's graphical modelling tools require Flash, but here's a preview of some of the content you'll see once
Flash is enabled:
Investment Overview for Merck (NYSE:MRK)
Key drivers of Merck's value that present opportunities for upside or downside to the current Trefis price estimate for Merck:
Nasonex & Other Anti-Infectives
Merck's Nasonex and Other Anti-Infectives Sales : We expect the Merck's revenues from anti-infective drugs to increase from roughly $9.45 billion in 2014 to around $11.8 billion by the end of our forecast period. However, there could be an upside of roughly 5% if this figure was to reach $14.5 billion instead. This could happen if drugs and vaccines such as Isentress and Gardasil expand rapidly overseas.
Merck's Gross Margin
- Merck's Gross Margin: We expect Merck's gross margin to remain more or less around current levels of about 70%. However, there could be 5% downside to our price estimate if margins were to fall further to 66% as Merck's revenue growth continues to remain under pressure. On the other hand there could be an upside of more than 5% if these margins were to increase to 76%, a level seen in 2012.
Merck is currently the world's second largest pharmaceutical company after Pfizer in terms of revenues. The company delivers innovative health care solutions through its prescription medicines, vaccines, biologic therapies, animal health and consumer care products which it markets directly and through its joint ventures. The firm's operations are managed through the company's four main divisions, namely Pharmaceutical, Animal Health, Consumer Care and the Alliances division.
The biggest contribution to the value of the stock comes from the Anti-Infectives division. This is explained by the following reasons.
Isentress delivers promising results
Worldwide sales of Isentress, an HIV integrase inhibitor for use in combination with other anti-retroviral agents for the treatment of HIV-1 infection in treatment-naive and treatment-experienced adults, were over $1.67 billion in 2014. Sales growth in recent periods reflects positive performance in the United States, as well as internationally, resulting from continued uptake since launch.
Gardasil gaining popularity
Since September 2012, Gardasil is being used in the HPV vaccination program to protect girls from cervical cancer across schools in the U.K, according to the U.K. Department of Health. This reflects a switch from GlaxoSmithKline’s Cervarix. Continuance of such switch in other countries will drive the sales growth.
Launch of new drugs
Merck believes that its anti-PD-1 therapy for oncology and ACE inhibitor for Alzheimer’s disease have the capability to change the course of medication. The FDA had granted breakthrough status to its anti-PD 1 drug Keytruda (Lambrolizumab) in April 2014, and subsequently approved it in September 2014. Keytruda is PD-1 specific monoclonal antibody for the treatment of advanced malignancy.
Loss of patents impacting sales
Like other major pharmaceutical companies, Merck is also battling against the impact of patent expiry of its several major drugs including Singulair, Propecia, Clarinex, Maxalt, Cozaar and Hyzaar. Out of these, asthma drug Singulair has had the biggest impact and has continually weighed on Merck’s growth for the past few quarters.
In addition, Merck’s cardiovascular division has also been hurt by the patent cliff as its drugs Cozaar/Hyzaar, which garnered over $2.1 billion in revenue in 2010, lost patent exclusivity in large markets including the U.S. and Europe in late 2010. Annual sales have fallen by 62% since then, amounting to $800 million in 2014. Additionally, Propecia, Clarinex and Maxalt together accounted for roughly $1.46 billion in revenues in 2012. This figure dropped sharply to less than $650 million in 2014 as a result of patent expiry.
Growing threat of generic products
The fast growing pharma market in emerging economies or referred to as the 'Pharmerging' economies have the capability and technical prowess to manufacture generic versions of blockbuster drugs. These generic drugs are often sold at prices that are substantially cheaper then their branded counterparts, thereby severely affecting big pharma's ability to generate profits in the long run.
Lack of approval for Biosimilars by FDA
At present the Food & Drug Administration Authority (FDA) does not have a solid process to grant approvals for Biosimilars.
Though its hard to say when such a process would be initiated, the potential impacts would be severe for any big pharmaceutical firm, as Biologics seem to be the last bastion of long term profits for big pharma.
Globalization of healthcare reforms
Governments around the world are trying to rein in fiscal spending in order to manage their budget deficits.
Since healthcare costs are one of the biggest components of any national budget, it is expected that an increase in healthcare legislation and reforms around the world will hurt revenues for the entire pharmaceutical sector.
How Does Trefis Modelling Work?
How do we get the historical numbers for this chart?
Trefis has a team of in-house Analysts who gather historical data from company filings and other verifiable sources. When historicals are available, we explain how we got them at the bottom of the Trefis analysis section below.
Who came up with the Trefis forecast for future years?
The Trefis team of in-house Analysts considers a variety of factors when projecting any forecast. The rationale for our projections is explained in the Trefis analysis section below.
How does my dragging the trendline on the chart impact the stock price?
- We use forecasts for business drivers to calculate forecasted Revenues and Profits for each division of the company.
- We then use forecasted Profits in a Discounted Cash Flow (DCF) model to obtain the Price Estimate for the company.
See more on: DCF Methodology
View All Help Topics